Uhelski, Anna-Carson Rimer
Blackford, Amanda L.
Sheng, Jennifer Y.
Snyder, Claire
Lehman, Jennifer
Visvanathan, Kala
Lim, David
Stearns, Vered
Smith, Karen Lisa
Funding for this research was provided by:
Susan G. Komen Foundation
Centers for Disease Control and Prevention (5 NU58DP006673, 5 NU58DP006673)
Article History
Received: 28 November 2022
Accepted: 22 May 2023
First Online: 1 June 2023
Declarations
:
: Claire Snyder MHS PhD reports research funding to the institution from Genentech and Pfizer, and consulting fees from Janssen (via Health Outcomes Solutions).Kala Visvanathan MD MHS reports funding from Cepheid and non-financial support from Optra Health Inc.Vered Stearns MD reports research funding to institution from Abbvie, Biocept, Novartis, Pfizer, Puma Biotechnology and QUE Oncology. Vered Stearns also served on an advisory board for Novartis 10/25/2021. In addition, Vered Stearns is Chair of a data safety monitoring board for AstraZeneca and received non-financial support from Foundation Medicine for study assays.Karen Lisa Smith MD MPH has received research support (to institution) from Pfizer. Karen Lisa Smith’s spouse has stock ownership in ABT Labs and Abbvie.The following authors declare that they have no conflicts of interest:Anna-Carson Rimer Uhelski MD.Amanda L. Blackford ScM.Jennifer Y. Sheng MDJennifer Lehman BSDavid Lim MS
: This study was approved by the Johns Hopkins Institutional Review Board.
: All participants provided informed consent.